A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit

Brazilian Journal of Infectious Diseases

Volumn 11, Issue 2, 2007, Pages 183-185

  Kiffer, Carlos R V ^a   Kuti, Joseph L ^b   Mendes, Caio M F ^a   Oplustil, Carmen P ^a   Amarante, Jorge B ^c   Biancalana, Maria L ^c   Xavier, Nelson ^c   Nicolau, David P ^b  

^a Fleury   (Brazil)

^b HARTFORD HOSPITAL   (United States)

^c HOSPITAL SAMARITANO   (Brazil)

Author keywords

Carbapenen; Meropenem; Pharmacodynamics; Resistance

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BRAZIL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG INFUSION; DRUG MEGADOSE; EMPIRICISM; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA;

EID: 34547127624     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702007000200001     Document Type: Article

References (14)

1. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
2. Kollef M.H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31:S131-8.
3. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate: antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
4. Rello J., Gallego M., Mariscal D., et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:196-200.
5. Trouillet J.L., Chastre J., Vuagnat A., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531-539.
6. Gillespie E.L., Kuti J.L., Nicolau D.P. When "S" doesn't mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infections. Conn Med 2005;69:203-10.
7. Kuti J.L., Moss K.M., Nicolau D.P., Knauft F.R. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: Application of pharmacodynamic concepts to meropenem therapy. Pharmacother 2004;24:1641-5.
8. Maglio D., Kuti J.L., Nicolau D.P. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program. Clin Ther 2005;27:1032-42.
9. Sun H.K., Kuti J.L., Nicolau D.P. Pharmacodynamics of antimicrobials for the empiric treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med 2005;33:2222-7.
10. Ambrose P.G., Bhavnani S.M., Jones R.N. Pharmacokinetics-pbarmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum b-lactamases: report from the ARREST Program. Antimicrob Agents Chemother 2003; 47:1643-6.
11. Drusano G.L., Preston S.L., Hardalo C., et al. Use of preclinical data for selection of a Phase II/III dose for evernimicin and identification of a preclinical breakpoint. Antimicrob Agents Chemother 2001; 45:13-22.
12. Kiffer C.R.V., Mendes C., Kuti J.L., Nicolau D.P. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn Microbiol Infect Dis 2004;49:109-16.
13. Kuti J.L., Nightingale C.H., Quintiliani R., Nicolau D.P. Pharmacodynamic profile of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis 2002;44:51-7.
14. Tam V.H., Louie A., Lomaestro B.M., Drusano G.L. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacother 2003; 23:291-5.